Current filters:


1 to 9 of 14 results

Oncologists backing of combo products supporting cytotoxic market


The popularity of combination therapies in the treatment of cancer is set to increase, which will help…

BiotechnologyGemzarMarkets & MarketingOncologyPharmaceuticalTaxotere

US oncologists see FOLFIRINOX as the most efficacious for advanced pancreatic cancer


The majority of surveyed US oncologists (57%) identified FOLFIRINOX* as the most efficacious treatment…

Eli LillyFOLFIRINOXGemzarMarkets & MarketingNorth AmericaOncologyPharmaceutical

Increased uptake of FOLFIRINOX and launch of Abraxane will see dynamic change in treatment of pancreatic cancer patients


Although the pancreatic cancer drug market will remain relatively flat through 2019 in the leading markets…

AbraxaneCelgeneEli LillyFOLFIRINOXGemzarMarkets & MarketingOncologyPharmaceutical

Pancreatic cancer has high rate of failures in late-stage clinical trials


The pancreatic cancer market has fewer competitors than most cancer markets, despite being one of the…

Eli LillyGemzarMarkets & MarketingOncologyPharmaceuticalResearch

1 to 9 of 14 results

Back to top